AU2005237269B2 - Immune response stimulating composition comprising methyl vinyl ether-maleic anhydride copolymer - based nanoparticles - Google Patents

Immune response stimulating composition comprising methyl vinyl ether-maleic anhydride copolymer - based nanoparticles Download PDF

Info

Publication number
AU2005237269B2
AU2005237269B2 AU2005237269A AU2005237269A AU2005237269B2 AU 2005237269 B2 AU2005237269 B2 AU 2005237269B2 AU 2005237269 A AU2005237269 A AU 2005237269A AU 2005237269 A AU2005237269 A AU 2005237269A AU 2005237269 B2 AU2005237269 B2 AU 2005237269B2
Authority
AU
Australia
Prior art keywords
nanoparticles
antigen
allergen
extract
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005237269A
Other languages
English (en)
Other versions
AU2005237269A1 (en
Inventor
Marta Ferrer Puga
Carlos Gamazo De La Rasilla
Sara Gomez Martinez
Juan Manuel Irache Garreta
Javier Ochoa Reparaz
Hesham H.A. Salman
Beatriz San Roman Aberasturi
Maria Luisa Sanz Larruga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoup Farma SL
Original Assignee
Innoup Farma S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innoup Farma S L filed Critical Innoup Farma S L
Publication of AU2005237269A1 publication Critical patent/AU2005237269A1/en
Application granted granted Critical
Publication of AU2005237269B2 publication Critical patent/AU2005237269B2/en
Assigned to UNIVERSIDAD DE NAVARRA reassignment UNIVERSIDAD DE NAVARRA Request to Amend Deed and Register Assignors: INSTITUTO CIENTIFICO Y TECNOLOGICO DE NAVARRA, S.A
Assigned to INNOUP FARMA, S.L. reassignment INNOUP FARMA, S.L. Request for Assignment Assignors: UNIVERSIDAD DE NAVARRA
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2005237269A 2004-04-29 2005-04-28 Immune response stimulating composition comprising methyl vinyl ether-maleic anhydride copolymer - based nanoparticles Expired AU2005237269B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200401023 2004-04-29
ES200401023A ES2246695B1 (es) 2004-04-29 2004-04-29 Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
PCT/ES2005/000225 WO2005105056A1 (es) 2004-04-29 2005-04-28 Composición estimuladora de la respuesta inmunitaria que comprende nanopartículas a base de un copolímero de metil vinil éter y anhídrido maleico

Publications (2)

Publication Number Publication Date
AU2005237269A1 AU2005237269A1 (en) 2005-11-10
AU2005237269B2 true AU2005237269B2 (en) 2011-08-11

Family

ID=35241413

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005237269A Expired AU2005237269B2 (en) 2004-04-29 2005-04-28 Immune response stimulating composition comprising methyl vinyl ether-maleic anhydride copolymer - based nanoparticles

Country Status (12)

Country Link
US (1) US8895067B2 (enExample)
EP (1) EP1752141B1 (enExample)
JP (1) JP4932704B2 (enExample)
CN (1) CN1976687B (enExample)
AU (1) AU2005237269B2 (enExample)
BR (1) BRPI0509828B1 (enExample)
CA (1) CA2564974C (enExample)
DE (1) DE602005015441D1 (enExample)
ES (2) ES2246695B1 (enExample)
MX (1) MXPA06012527A (enExample)
RU (1) RU2379028C2 (enExample)
WO (1) WO2005105056A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246695B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US7396886B2 (en) * 2005-06-21 2008-07-08 Isp Investments Inc. Process for making copolymers of maleic anhydride and alkyl vinyl ether of high specific viscosity
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
ES2286951B1 (es) * 2006-05-26 2008-10-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
BRPI0817664A2 (pt) 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
JP2010077057A (ja) * 2008-09-25 2010-04-08 Kagoshima Univ 抗食物アレルギーワクチン
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US10184937B2 (en) * 2009-03-31 2019-01-22 United Arab Emirates University Minimally invasive assessment of IgE mediated allergy
WO2010138193A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
US20110293700A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
EP2510930A1 (en) * 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
ES2369949B1 (es) * 2011-05-19 2013-08-13 Universidade De Santiago De Compostela Microesferas poliméricas como adyuvantes en la producción de vacunas frente a parásitos escuticociliados de peces.
CN109172819A (zh) 2011-07-29 2019-01-11 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
KR20250052503A (ko) 2012-06-21 2025-04-18 노쓰웨스턴유니버시티 펩티드 접합된 입자
EP3760223A1 (en) 2013-04-03 2021-01-06 N-Fold Llc Nanoparticle composition for desensitizing a subject to peanut allergens
US9668970B2 (en) * 2013-12-02 2017-06-06 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US10272038B2 (en) 2013-12-02 2019-04-30 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
JP6706261B2 (ja) 2014-12-01 2020-06-03 インノウプ、ファルマ、ソシエダッド、リミターダＩｎｎｏｕｐ Ｆａｒｍａ， Ｓ．Ｌ． 化合物を封入するためのナノ粒子、その製造および使用
CN112057610A (zh) * 2019-06-10 2020-12-11 中国科学院宁波材料技术与工程研究所 一种超小纳米免疫增强剂-抗原复合纳米粒子及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
WO2002069938A1 (es) * 2001-03-06 2002-09-12 Instituto Cientifico Y Tecnologico De Navarra, S.A. Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas
US20030147965A1 (en) * 2001-12-10 2003-08-07 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
GB8601100D0 (en) 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
SE8900422D0 (sv) 1989-02-08 1989-02-08 Pharmacia Ab Tvaerbundna hyaluronatgeler samt foerfarande foer framstaellning av dessa
IT1247472B (it) 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
EP0544259A1 (en) 1991-11-27 1993-06-02 Lignyte Co., Ltd. Water insoluble biocompatible hyaluronic and polyion complex and method of making the same
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US20010053359A1 (en) 1994-07-26 2001-12-20 Peter Watts Drug delivery composition for the nasal administration of antiviral agents
KR970705401A (ko) 1994-08-30 1997-10-09 사무엘 시몬 에스큘라이 세포활성의 조정용 히알루론산과 그 유도체(hyaluronic acid and derivatives for modulation of cellular activity)
ES2098188B1 (es) 1995-05-11 1997-12-16 Univ Santiago Compostela Desarrollo de nanoparticulas a base de polimeros hidrofilicos.
ES2098189B1 (es) 1995-05-23 1997-12-16 Fernandez Arenas Antonio Sistema para la toma de impresiones destinadas a la confeccion de protesis dentales implantosoportadas y medios para su realizacion.
DK0752245T3 (da) 1995-07-05 2002-09-09 Europ Economic Community Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler
WO1997004747A1 (en) 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
US7276251B2 (en) 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
ES2114502B1 (es) 1996-07-29 1999-07-01 Univ Santiago Compostela Aplicacion de nanoparticulas a base de polimeros hidrofilicos como formas farmaceuticas.
EP1021168A4 (en) 1997-10-09 2006-08-30 Univ Vanderbilt MICRO AND NANOAPARTICULAR, POLYMERIC ADMINISTRATION SYSTEM
DE19810965A1 (de) 1998-03-13 1999-09-16 Aventis Res & Tech Gmbh & Co Nanopartikel, Verfahren zu ihrer Herstellung und ihre Verwendung
FR2777193B1 (fr) 1998-04-14 2001-06-08 Coletica Particule a groupement hydroxamique chelatante d'ions metalliques et leur utilisation en cosmetique ou en pharmacie
FR2777895A1 (fr) 1998-04-28 1999-10-29 Debio Rech Pharma Sa Polymere sequence non-reticule,procede pour sa preparation, et ses utilisations
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
JP4526708B2 (ja) 1998-09-01 2010-08-18 メリオン リサーチ スリー リミテッド 細胞を媒介した免疫応答を誘導する方法及びそのための非経口ワクチン製剤
IN191203B (enExample) 1999-02-17 2003-10-04 Amarnath Prof Maitra
WO2000064954A1 (en) 1999-04-22 2000-11-02 Vanderbilt University Polymeric encapsulation system promoting angiogenesis
AU1186401A (en) 1999-06-23 2001-01-22 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
US20020009466A1 (en) 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
US7189392B1 (en) 1999-10-15 2007-03-13 Genetics Institute, Llc Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins
US6743446B2 (en) 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
AU4477001A (en) 2000-04-18 2001-10-30 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
AU2001262596A1 (en) 2000-05-03 2001-11-12 Natural As Compositions containing aminopolysaccharides and negatively charged polysaccharides
US6773695B2 (en) * 2000-10-05 2004-08-10 Mannkind Corporation Modulation of allergic response
KR100375299B1 (ko) 2000-10-10 2003-03-10 주식회사 엘지생명과학 히알루론산의 가교결합형 아마이드 유도체와 이의 제조방법
ES2221530B1 (es) 2002-07-19 2006-02-16 Universidad De Santiago De Compostela Nanoparticulas para la administracion de ingredientes activos,procedimiento para la elaboracion de dichas particulas y composicion que las contienen.
US7273327B2 (en) 2003-06-20 2007-09-25 Colgate-Palmolive Company Oral care implement
ATE428730T1 (de) 2003-08-12 2009-05-15 Octapharma Ag Verfahren zur herstellung einer alpha-1- antitrypsinlösung
ES2246695B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
WO2002069938A1 (es) * 2001-03-06 2002-09-12 Instituto Cientifico Y Tecnologico De Navarra, S.A. Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas
EP1369110A1 (en) * 2001-03-06 2003-12-10 Instituto Cientifico Y Tecnologico De Navarra, S.A. Production of nanoparticles from methyl vinyl ether copolymer and maleic anhydride for the administration of hydrophilic pharmaceuticals, more particularly of puric and pyrimidinic bases
US20030147965A1 (en) * 2001-12-10 2003-08-07 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles

Also Published As

Publication number Publication date
ES2246695A1 (es) 2006-02-16
EP1752141B1 (en) 2009-07-15
MXPA06012527A (es) 2007-04-10
US20070224225A1 (en) 2007-09-27
CN1976687A (zh) 2007-06-06
ES2246695B1 (es) 2007-05-01
BRPI0509828A (pt) 2007-11-27
JP2007534728A (ja) 2007-11-29
JP4932704B2 (ja) 2012-05-16
DE602005015441D1 (de) 2009-08-27
RU2379028C2 (ru) 2010-01-20
BRPI0509828B1 (pt) 2021-07-13
AU2005237269A1 (en) 2005-11-10
CA2564974A1 (en) 2005-11-10
WO2005105056A1 (es) 2005-11-10
EP1752141A1 (en) 2007-02-14
CN1976687B (zh) 2010-05-05
US8895067B2 (en) 2014-11-25
ES2329598T3 (es) 2009-11-27
CA2564974C (en) 2013-07-02
RU2006142094A (ru) 2008-06-20

Similar Documents

Publication Publication Date Title
AU2005237269B2 (en) Immune response stimulating composition comprising methyl vinyl ether-maleic anhydride copolymer - based nanoparticles
Singh et al. Diphtheria toxoid loaded poly-(ε-caprolactone) nanoparticles as mucosal vaccine delivery systems
Rose et al. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522
JP5417354B2 (ja) 免疫調節不全を含む疾患の治療のためのグラム陽性細菌調製物
EP2262480B1 (en) Immunomodulator particles
US8889623B2 (en) Immunostimulatory nanoparticles and related compositions, methods and systems
US9585955B2 (en) Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
JP6534146B2 (ja) ワクチン用アジュバント、ワクチン、及び免疫誘導方法
Murillo et al. A Brucella ovis antigenic complex bearing poly-ε-caprolactone microparticles confer protection against experimental brucellosis in mice
Afshari et al. Immunogenicity evaluating of the SLNs-alginate conjugate against Pseudomonas aeruginosa
Florindo et al. New approach on the development of a mucosal vaccine against strangles: systemic and mucosal immune responses in a mouse model
WO2013110050A1 (en) Inulin and inulin acetate formulations
Jiang et al. Controlled release of Bordetella bronchiseptica dermonecrotoxin (BBD) vaccine from BBD-loaded chitosan microspheres in vitro
Saraf et al. Acid resilience oral mucosal delivery for vaccination against Hepatitis-B
Măruţescu et al. Nanomedicine progress in prevention, detection, and treatment of tuberculosis

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ IMMUNE RESPONSE STIMULATING COMPOSITION COMPRISING METHYL VINYL ETHER-MALEIC ANHYDRIDE COPOLYMER - BASED NANOPARTICLES

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: INNOUP FARMA, S.L.

Free format text: FORMER OWNER(S): UNIVERSIDAD DE NAVARRA

MK14 Patent ceased section 143(a) (annual fees not paid) or expired